David Cherney

Featured in: Favicon

forbes.com Favicon

medscape.com Favicon

thelancet.com Favicon

healio.com Favicon

utilitydive.com + 6 more

Articles

Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart Failure:

Nov 1, 2024 | jacc.org | Mikhail Kosiborod |David Cherney |Akshay S. Desai |Jeffrey M. Testani

AbstractBackgroundMineralocorticoid receptor antagonists (MRA) improve outcomes in patients with heart failure and reduced ejection fraction (HFrEF) but are underused in clinical practice. Observational data suggest that hyperkalemia is the leading obstacle for the suboptimal use of MRA. ObjectivesWe evaluated the effects of sodium zirconium cyclosilicate (SZC) in optimizing use of spironolactone among participants with HFrEF and hyperkalemia.
Inter‐relationships between cardiovascular, renal and metabolic diseases: Underlying evidence and implications for integrated interdisciplinary care and management

Feb 8, 2024 | dom-pubs.onlinelibrary.wiley.com | Jiten Vora |David Cherney |Mikhail Kosiborod |Jonas Spaak

CONFLICT OF INTEREST STATEMENT Jiten Vora has received consulting fees from Boehringer Ingelheim and Bayer and honoraria for participation in an Emirates Diabetes Endocrinology meeting.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →